title: D1 and D2 dopamine and opiate receptors are involved in the restraint stress-induced sensitization to the psychostimulant effects of amphetamine.
abstract: The time course of the restraint stress-induced sensitization to the stimulant effects of amphetamine (AMPH, 0.5 mg/kg IP) on locomotor activity was investigated for up to 8 days. In a series of separate experiments, the involvement of opioid and dopaminergic mechanisms in the development of acute restraint stress-induced behavioral sensitization were characterized. Both a single restraint session (2 h) and chronic restraint (2 h per day for 7 days) similarly potentiated the effects of AMPH on motor activity. This behavioral sensitization was prevented by the administration of naltrexone (2 mg/kg IP), haloperidol (1 mg/kg IP), sulpiride (60 mg/kg IP) or SCH23390 (0.5 mg/kg IP) 10-20 min prior to restraint. These results indicate that 1) the development of sensitization to amphetamine-induced effects on motor activity does not depend on the length of exposure to stress (acute or chronic). 2) the stimulation of both D1 and D2 dopaminergic receptors is necessary for the development of the restraint stress-induced sensitization to AMPH and 3) and opioid system is also implicated in this sensitization process.
authors.affiliation: Departamento de Farmacología, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Argentina.
authors.forename: C S
authors.initials: CS
authors.lastname: Díaz-Otañez
authors.forename: N R
authors.initials: NR
authors.lastname: Capriles
authors.forename: L M
authors.initials: LM
authors.lastname: Cancela
mesh_terms: D000661:Amphetamine / Q000494:pharmacology*; D000818:Animals; D000697:Central Nervous System Stimulants / Q000494:pharmacology*; D018492:Dopamine Antagonists / Q000494:pharmacology; D065127:Dopamine D2 Receptor Antagonists; D018765:Dopamine Uptake Inhibitors / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D009271:Naltrexone / Q000494:pharmacology; D009292:Narcotic Antagonists; D051381:Rats; D017208:Rats, Wistar; D017447:Receptors, Dopamine D1 / Q000037:antagonists & inhibitors / Q000502:physiology*; D017448:Receptors, Dopamine D2 / Q000502:physiology*; D011957:Receptors, Opioid / Q000502:physiology*; D012149:Restraint, Physical; D013315:Stress, Psychological / Q000503:physiopathology* / Q000523:psychology*; D013997:Time Factors
chemical_list: D000697:Central Nervous System Stimulants; D018492:Dopamine Antagonists; D065127:Dopamine D2 Receptor Antagonists; D018765:Dopamine Uptake Inhibitors; D009292:Narcotic Antagonists; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D011957:Receptors, Opioid; D009271:Naltrexone; D000661:Amphetamine